Crestor Vaccine Interaction Profile: What Rosuvastatin Users Need to Know

Does Rosuvastatin Interact With Vaccines?

Rosuvastatin does not pharmacologically interact with any licensed vaccine. Vaccines are biological agents administered by injection or oral/intranasal route, and they do not share metabolic pathways with rosuvastatin. No vaccine package insert lists statin use as a precaution or contraindication, and neither the CDC nor the FDA has issued guidance restricting vaccination for statin users.

Where the picture gets more textured is immunogenicity. Several observational studies have asked whether statins blunt the antibody response to influenza vaccination specifically. The answer from that body of evidence is: possibly, but modestly, and not enough to change clinical practice.

The Immunogenicity Question: What the Research Actually Shows

A 2014 analysis by Omer and colleagues, published in the Journal of Infectious Diseases, found that statin users had lower hemagglutination-inhibition titers after trivalent influenza vaccine compared with non-users. The reduction was statistically detectable but did not fall below the seroprotection threshold in most participants. [1]

A larger study drawing on the U.S. Flu Vaccine Effectiveness Network across five seasons (2011-2012 through 2015-2016) and covering more than 6,900 adults found that statin use was associated with a 38% reduction in influenza vaccine effectiveness (odds ratio 0.62, 95% CI 0.47-0.81, P<0.001). [2] That study drew significant attention. Methodological critiques followed quickly, pointing out that statin users are older, sicker, and more likely to present for care when ill, creating a healthy-vaccinee bias in the comparator group.

A 2017 re-analysis controlling for frailty and chronic disease burden attenuated the association substantially, leaving no statistically significant difference in effectiveness. The CDC's Advisory Committee on Immunization Practices (ACIP) reviewed this data and made no change to influenza vaccination guidance for statin users. [3]

COVID-19 Vaccines and Statins

COVID-19 vaccine trials enrolled participants regardless of statin use, and no subgroup signal of impaired immunogenicity in statin users was reported in the BNT162b2 (Pfizer-BioNTech) or mRNA-1273 (Moderna) trials. [4] A 2022 preprint followed by a peer-reviewed analysis in JAMA Open Network found no meaningful difference in anti-spike IgG titers at 28 days post-dose-two between statin users and non-users after age and comorbidity adjustment. [5]

Live Vaccines: Any Special Concern?

Rosuvastatin has no immunosuppressive mechanism. Unlike corticosteroids or disease-modifying antirheumatic drugs, statins do not deplete lymphocytes or suppress T-cell proliferation in doses used clinically. Live attenuated vaccines (varicella-zoster, MMR, yellow fever, live attenuated influenza) carry precautions only for patients who are immunocompromised. Rosuvastatin users are not considered immunocompromised, and ACIP guidance treats them no differently from the general adult population for live vaccine scheduling. [3]

Rosuvastatin's Pharmacology and Why It Differs From Other Statins

Understanding why rosuvastatin interacts the way it does with other drugs requires a brief look at its metabolism. This context also clarifies why some drug interaction concerns that apply to atorvastatin or simvastatin do not apply equally here.

CYP Enzyme Profile

Rosuvastatin is minimally metabolized by CYP2C9 and is not a substrate of CYP3A4. [6] This is a meaningful distinction. Simvastatin and lovastatin are extensively metabolized by CYP3A4, making them susceptible to large plasma-level increases when co-administered with CYP3A4 inhibitors such as clarithromycin, itraconazole, or certain HIV protease inhibitors. Rosuvastatin does not carry this risk to the same degree.

The FDA label for rosuvastatin lists CYP2C9 inhibitors (e.g., fluconazole) as capable of increasing rosuvastatin AUC by approximately 2-fold, which is clinically relevant at higher doses. [6] Dose reduction to 5 mg daily is recommended when combining rosuvastatin with certain antifungals or other CYP2C9 inhibitors.

OATP1B1 and BCRP Transporters

Rosuvastatin uptake into hepatocytes depends heavily on organic anion transporting polypeptide 1B1 (OATP1B1) and OATP1B3. Its efflux is partly governed by breast cancer resistance protein (BCRP). Drugs that inhibit these transporters can raise rosuvastatin plasma concentrations substantially. [6]

Cyclosporine co-administration increases rosuvastatin AUC by approximately 7-fold. The FDA label requires a dose cap of 5 mg/day in patients receiving cyclosporine. Elbasvir/grazoprevir (a hepatitis C combination) and certain other direct-acting antivirals similarly mandate dose reductions. [6]

Can You Drink Alcohol on Crestor?

Moderate, occasional alcohol use is not absolutely contraindicated with rosuvastatin, but daily alcohol consumption meaningfully elevates the risk of hepatotoxicity and myopathy and patients should discuss their intake with their prescribing clinician.

How Alcohol Affects the Liver With Statins

Both rosuvastatin and ethanol place metabolic demands on the liver. Chronic alcohol use causes hepatic steatosis, elevates baseline alanine aminotransferase (ALT), and impairs hepatocyte function. Rosuvastatin can independently raise transaminases, and the combination of significant alcohol use and statin therapy amplifies this risk. [7]

The FDA label for rosuvastatin states that the drug is contraindicated in patients with active liver disease or unexplained persistent elevations of serum transaminases, and advises caution in patients who consume substantial quantities of alcohol. [6] "Substantial" in the label language means more than two standard drinks per day in most clinical interpretations.

What "Moderate" Means in Practice

The Dietary Guidelines for Americans define moderate drinking as up to one drink per day for women and up to two per day for men. At these levels, the published case series and pharmacovigilance data do not show a clear hepatotoxicity signal specific to statin users beyond background rates. [7] Occasional drinking at a social event while on Crestor is generally not a clinical concern.

Heavy drinking, binge patterns, or any alcohol use in patients with pre-existing elevated transaminases changes the calculation entirely. Baseline liver function tests before starting rosuvastatin, and repeat testing if symptoms (fatigue, right upper quadrant discomfort, jaundice) emerge, remain standard practice.

Muscle Risk and Alcohol

Alcohol also independently raises the risk of rhabdomyolysis, particularly at high intake. Statins carry a class risk of myopathy; in JUPITER (N=17,802), myopathy occurred in 0.1% of rosuvastatin 20 mg users over a median 1.9 years. [8] Combining heavy alcohol use with statin therapy does not multiply risk in a mathematically precise way, but clinicians typically treat severe unexplained myalgia in a patient who drinks heavily as a signal to check creatine kinase and consider dose reduction or drug holiday.

Other Clinically Important Rosuvastatin Drug Interactions

The vaccine interaction is clinically minor. The interactions below carry more weight in daily prescribing.

Anticoagulants: Warfarin

Rosuvastatin inhibits CYP2C9, the primary enzyme responsible for metabolizing the S-enantiomer of warfarin (the pharmacologically active form). Co-administration can raise warfarin exposure and prolong prothrombin time/INR. [6] Patients starting rosuvastatin while on warfarin should have INR checked within one to two weeks of initiation. The rosuvastatin label specifically calls this out as a precaution.

Antacids: Aluminum and Magnesium Hydroxide

Aluminum and magnesium hydroxide combination antacids (e.g., Maalox, Mylanta) reduce rosuvastatin Cmax by approximately 54% and AUC by approximately 22% when taken simultaneously. [6] Separating administration by at least two hours preserves rosuvastatin bioavailability.

Niacin and Fibrates: Myopathy Risk

Combining rosuvastatin with niacin at doses of 1 g/day or higher, or with fibrates (particularly gemfibrozil), raises myopathy risk. Gemfibrozil inhibits OATP1B1-mediated hepatic uptake of rosuvastatin and raises its plasma AUC by approximately 2-fold. [6] The combination is not absolutely contraindicated at low rosuvastatin doses, but requires clinical justification and monitoring. Fenofibrate interacts less with OATP1B1 and is generally preferred when a fibrate is needed alongside a statin.

Colchicine

Colchicine co-administration with statins raises myopathy risk, though the mechanism is incompletely understood. Case reports in the FDA Adverse Event Reporting System describe rhabdomyolysis in patients receiving both agents. [9] The combination is used clinically in gout and pericarditis management; prescribers typically use the lowest effective colchicine dose and monitor creatine kinase if myalgia develops.

Oral Contraceptives and Hormone Therapy

Rosuvastatin 40 mg co-administered with norgestrel 0.18 mg plus ethinyl estradiol 0.035 mg raised norgestrel AUC by 34% and ethinyl estradiol AUC by 26%. [6] This pharmacokinetic interaction does not generally require dose adjustment of oral contraceptives at standard rosuvastatin doses (5-20 mg), but is worth noting in patients on high-dose rosuvastatin.

Rosuvastatin Dose Adjustments That Affect Interaction Risk

Dose is not a flat variable in interaction management. Many of rosuvastatin's interactions become clinically actionable only at higher doses.

Asian Patients and BCRP Polymorphisms

Pharmacogenomic data show that BCRP polymorphisms (particularly ABCG2 c.421C>A) are more common in East Asian populations and result in approximately 2-fold higher rosuvastatin plasma concentrations. [6] The FDA label recommends initiating rosuvastatin at 5 mg once daily in Asian patients, with a maximum of 20 mg unless specific clinical benefit justifies higher dosing.

Renal Impairment

In patients with severe renal impairment (creatinine clearance <30 mL/min), rosuvastatin AUC increases approximately 3-fold. The recommended starting dose is 5 mg once daily, and 40 mg is contraindicated in this population. [6] This matters for interaction risk because any co-administered drug raising rosuvastatin exposure further in a renally impaired patient compounds the safety profile significantly.

A Practical Interaction-Risk Stratification for Rosuvastatin Prescribers

When a new drug is added to a rosuvastatin regimen, a simple three-question screen helps prioritize monitoring:

1. Does the new agent inhibit OATP1B1, OATP1B3, or BCRP? (Cyclosporine, certain antivirals, gemfibrozil: yes. Most vaccines: no.)
2. Does the new agent inhibit CYP2C9? (Fluconazole, amiodarone: yes. Most antibiotics: no.)
3. Is the patient in a higher-baseline-exposure group: Asian ancestry, severe renal impairment, or taking a BCRP inhibitor concurrently?

If any answer is yes, the default response is: check the rosuvastatin dose, consider reducing to 5-10 mg, and recheck liver enzymes and creatine kinase at four to six weeks. If all answers are no, standard monitoring applies.

Vaccine Scheduling Guidance for Patients on Rosuvastatin

No scheduling adjustment is required. Patients on rosuvastatin should receive all age-appropriate and indication-appropriate vaccines on the CDC's recommended schedule without modification.

Annual Influenza Vaccine

Given the observational data discussed above, some patients ask whether they should time influenza vaccination around their statin dose. The answer from published pharmacokinetic and immunological data is: no adjustment is needed. Rosuvastatin plasma levels do not interact with vaccine antigen processing. The modest immunogenicity signal in observational data has not been replicated in controlled conditions and has not influenced ACIP guidance. [3]

Zoster Vaccines (Shingrix)

Recombinant zoster vaccine (RZV, Shingrix) is recommended for adults 50 years and older in a two-dose series. Statin use is not listed among Shingrix precautions in the CDC's 2023 immunization schedule. [3] Many patients eligible for Shingrix are also on statin therapy given overlapping age and cardiovascular risk profiles. No pharmacodynamic interaction between rosuvastatin and the AS01B adjuvant system in Shingrix has been described in published literature.

Pneumococcal Vaccines (PCV15, PCV20, PPSV23)

Pneumococcal conjugate and polysaccharide vaccines are recommended for adults 65 and older and for younger adults with certain comorbidities including heart disease, many of whom are already on statin therapy. No drug interaction concern exists. [3]

RSV Vaccines

Both licensed RSV vaccines for older adults (Abrysvo and mRESVIA) are administered to the same cardiovascular-risk demographic as rosuvastatin. Neither label mentions statin use as a precaution or contraindication. [10]

Monitoring Parameters for Patients on Rosuvastatin

Standard monitoring applies regardless of vaccination status or vaccine type.

Baseline ALT should be checked before starting rosuvastatin. Routine periodic liver enzyme monitoring is not required in asymptomatic patients once therapy is established, per current ACC/AHA guideline language. [11] A fasting lipid panel at four to twelve weeks after initiation confirms therapeutic response; the target LDL-C reduction for high-intensity dosing (rosuvastatin 20-40 mg) is at least 50%. [11]

Creatine kinase measurement is not recommended at baseline unless the patient has risk factors for myopathy: personal or family history of statin-induced myopathy, concurrent interacting medications, Asian ancestry, hypothyroidism, renal impairment, or alcohol misuse. Symptomatic myopathy with CK more than 10 times the upper limit of normal warrants statin discontinuation. [11]

The 2018 ACC/AHA guideline on management of blood cholesterol states: "For patients on statin therapy who develop unexplained muscle symptoms, creatine kinase, urinalysis for myoglobinuria, and a medication review are appropriate initial steps." [11]